ASCO 2024 | IOB-032/PN-E40: pembrolizumab with a IO102-IO103 in melanoma and SCCHN

Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, gives an overview of the Phase II IOB-032/PN-E40 trial (NCT05280314), which evaluating IO102-IO103, a therapeutic cancer vaccine, plus pembrolizumab as neoadjuvant and adjuvant treatment in melanoma and squamous cell carcinoma of the head and neck (SCCHN). The primary endpoint is major pathological response at surgery, with secondary endpoints including safety, event-free survival, and disease-free survival. The trial includes multiple cohorts with planned crossover for poor responders, and aims to enhance treatment outcomes in resectable melanoma and SCCHN. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.